MGC Diagnostics Corporation Added to the Russell Microcap Index

       MGC Diagnostics Corporation Added to the Russell Microcap Index

PR Newswire

ST. PAUL, Minn., July 1, 2013

ST. PAUL, Minn., July 1, 2013 /PRNewswire/ -- MGC Diagnostics Corporation
(NASDAQ: MGCD) a global medical technology company, announced today that the
Company was added to the Russell Microcap® Index effective at the close of the
market on June 28, 2013, when Russell Investments reconstituted its
comprehensive set of U.S. and global equity indexes.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

The Russell Microcap Index measures the performance of the microcap segment of
the U.S. equity market. Microcap stocks consist of the smallest 1,000
securities in the small-cap Russell 2000® Index, plus the next 1,000 eligible
securities, based on a ranking of all U.S. equities by market capitalization.
Membership in the Russell Microcap Index, which remains in place for one year,
means automatic inclusion in the appropriate growth and value style indexes.

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is
a global medical technology company dedicated to cardiorespiratory health
solutions. The Company develops, manufactures and markets non-invasive
diagnostic systems. This portfolio of products provides solutions for disease
detection, integrated care, and wellness across the spectrum of
cardiorespiratory healthcare. The Company's products are sold internationally
through distributors and in the United States through a direct sales force
targeting heart and lung specialists located in hospitals, university-based
medical centers, medical clinics, physicians' offices, pharmaceutical
companies, medical device manufacturers, and clinical research organizations
(CROs). For more information about MGC Diagnostics, visit
www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange
Commission, in press releases, and in other communications to shareholders or
the investing public, MGC Diagnostics Corporation may make forward-looking
statements concerning possible or anticipated future financial performance,
business activities or plans that include the words "believes," "expects,"
"anticipates," "intends" or similar expressions. For these forward-looking
statements, the Company claims the protection of the safe harbor for
forward-looking statements contained in federal securities laws. These
forward-looking statements are subject to a number of factors, risks and
uncertainties, including those disclosed in our periodic filings with the SEC,
that could cause actual performance, activities or plans after the date the
statements are made to differ significantly from those indicated in the
forward-looking statements. For a list of these factors¸ see the sections
entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking
Statements," in the Company's Form 10-K for the year ended October 31, 2012,
and any updates in subsequent filings on Form 10-Q or Form 8-K under the
Securities Exchange Act of 1934.

Contact: Wesley W. Winnekins     Joe Dorame, Robert Blum, Joe Diaz
         MGC Diagnostics Corporation     Lytham Partners, LLC
         Chief Financial Officer (602) 889-9700
         (651) 484-4874 mgcd@lythampartners.com

SOURCE MGC Diagnostics Corporation

Website: http://www.mgcdiagnostics.com